SANA
Sana Biotechnology Inc
NASDAQ · Biotechnology
$3.93
+0.38 (+10.70%)
Open$3.69
Previous Close$3.55
Day High$4.00
Day Low$3.69
52W High$6.55
52W Low$1.26
Volume—
Avg Volume2.38M
Market Cap1.05B
P/E Ratio—
EPS$-0.97
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+919.8% upside
Current
$3.93
$3.93
Target
$40.08
$40.08
$23.55
$40.08 avg
$57.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 204.77M | 187.81M | 190.12M |
| Net Income | 17.06M | 14.80M | 14.99M |
| Profit Margin | 8.3% | 7.9% | 7.9% |
| EBITDA | 24.96M | 25.10M | 25.01M |
| Free Cash Flow | 20.72M | 16.56M | 17.82M |
| Rev Growth | +11.7% | +19.4% | -6.7% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |